Heart Monitoring a Must for Breast Cancer Patients on Herceptin
TUESDAY, Aug. 7, 2018 -- The widely used chemotherapy drug trastuzumab (Herceptin) can be life-saving for women with HER2-positive breast cancer, a particularly aggressive form of the disease. But new research now adds to mounting evidence that the...
Condition: HER2-positive Breast Cancer Intervention: Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin Sponsor: Shandong University Not yet recruiting
ConclusionIt seems that inexperienced physicians may profit from the use of EndoPredict® to avoid an overtreatment. In nodal negative patients and patients with a low Ki67 index, undertreatment can be avoided with the use of EndoPredict® (borderline significance). Further prospective studies with larger study cohorts are needed to further validate this tool.
CONCLUSIONS: In the neoadjuvant setting, there is high- to low-certainty evidence of equivalent outcomes for the sequence in which taxanes are delivered. In the adjuvant setting, none of the studies reported on overall survival or disease-free survival. In most institutions, standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice. We wait for the full-text publication of a relevant neoadjuvant study for women with HER2-negative breast cancer for inclusion in an update of this review. PMID: 30776132 [PubMed - as supplied by publisher]
CONCLUSIONS: The primary endpoint of the study was met, by reaching the pre-specified pCRs. In patients selected using Ki67 reduction after short-term letrozole exposure, a meaningful pCR rate can be achieved without chemotherapy. PAM50 intrinsic subtyping further refines our ability to identify a subset of patients for whom chemotherapy might be spared. PMID: 30778520 [PubMed - as supplied by publisher]
ConclusionILC patients could derive significant DFS and OS benefits from CT, especially for high-risk patients.
Evidence from clinical trials suggests that the addition of bevacizumab to chemotherapy in the first-line treatment of patients with HER2-negative metastatic breast cancer improves progression-free survival (P...
AbstractHuman epidermal growth factor receptor 2 (HER2)‐targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression‐free survival among women with HER2‐positive metastatic breast cancer, but grade ≥3 cardiotoxicity occurs in approximately 8% of cases. Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti‐HER2 therapy in a 63‐year‐old woman who presented to the emergency department with an 8‐ to 10‐hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab‐paclitaxel chemo...
CONCLUSIONSFor patients with Luminal/HER2 negative breast cancer, the combination of the imaging features of the tumor and the mammary gland, obtained with 18F-FDG PET-CT at baseline and after the first cycle of NAC, may allow the physician to evaluate the probability of BCS.
CONCLUSIONS: Patients with HER2-positive MBC who received Tmab and Pmab treatment before T-DM1 have fewer benefits from T-DM1. PMID: 30737616 [PubMed - as supplied by publisher]
ConclusionsThis study suggests that the immunological differences between AA and Caucasian breast cancers represented by TCGA data are subtle, if they exist at all. We observed no consistent racial differences in immune gene expression or TIL counts in TNBC by race. However, this study cannot rule out small differences in immune cell subtype distribution and activity status that may not be apparent in bulk RNA analysis.